FY2027 EPS Estimates for AC Immune Cut by Leerink Partnrs

AC Immune SA (NASDAQ:ACIU) – Research analysts at Leerink Partnrs lowered their FY2027 EPS estimates for AC Immune in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of $0.06 for the year, down from their previous estimate of $0.12. The consensus estimate for AC Immune’s current full-year earnings is ($0.89) per share.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $91.60 million.

Several other equities analysts have also recently weighed in on ACIU. StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research note on Wednesday.

AC Immune Price Performance

NASDAQ:ACIU opened at $3.27 on Thursday. AC Immune has a 1 year low of $2.25 and a 1 year high of $5.14. The stock has a 50-day moving average price of $3.27 and a two-hundred day moving average price of $3.45.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after buying an additional 7,400 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of AC Immune in the second quarter valued at approximately $218,000. Renaissance Technologies LLC lifted its position in shares of AC Immune by 26.4% in the second quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock worth $2,602,000 after purchasing an additional 136,300 shares in the last quarter. Vanguard Capital Wealth Advisors acquired a new position in AC Immune during the second quarter worth $56,000. Finally, Assenagon Asset Management S.A. grew its position in AC Immune by 294.7% in the second quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after purchasing an additional 328,312 shares in the last quarter. 51.36% of the stock is owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.